Ernexa Therapeutics Inc.

NasdaqCM:ERNA Stock Report

Market Cap: US$6.9m

Ernexa Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Sanjeev Luther

Chief executive officer

US$888.8k

Total compensation

CEO salary percentage61.88%
CEO tenure2.5yrs
CEO ownershipn/a
Management average tenure2.2yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 11

Brooklyn Immunotherapeutics announces name change to Eterna Therapeutics

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) said on Tuesday that it was changing its name to Eterna Therapeutics Inc. to reflect its focus on developing therapies using its patented in-licensed mRNA cell engineering technologies. The name change will be effective Monday, October 17. The company's common stock will trade on the Nasdaq under the new ticker symbol "ERNA". (BTX) has risen ~5%.
Seeking Alpha • Jul 26

Brooklyn ImmunoTherapeutics releases head and neck cancer phase 2 trial results

A phase 2 trial of Brooklyn ImmunoTherapeutics' (NASDAQ:BTX) head and neck cancer candidate IRX-2 showed that the treatment tended to benefit patients more with later stage disease compared to those with earlier stages. The primary endpoint of the study was to estimate 2-year event-free survival (EFS). Secondary endpoints included overall survival and safety. Results showed that at two years of follow-up in the intention-to-treat population, median EFS was 48.3 months. Also, patients who received radiation only (no chemotherapy) as part of adjuvant therapy fared better than those who received both. Adverse events were higher in the treatment arm compared to the control arm. Brooklyn ImmunoTherapeutics (BTX) CEO Matt Angel said the results "provide a clear path forward for testing in patient populations that may benefit from treatment with IRX-2 in combination with checkpoint inhibitors." Brooklyn ImmunoTherapeutics (BTX), which is down ~89% year to date, is viewed as a strong sell by Seeking Alpha's Quant Rating.

CEO Compensation Analysis

How has Sanjeev Luther's remuneration changed compared to Ernexa Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$11m

Dec 31 2025US$889kUS$550k

-US$14m

Sep 30 2025n/an/a

-US$18m

Jun 30 2025n/an/a

-US$44m

Mar 31 2025n/an/a

-US$46m

Dec 31 2024US$3mUS$550k

-US$45m

Compensation vs Market: Sanjeev's total compensation ($USD888.81K) is above average for companies of similar size in the US market ($USD659.91K).

Compensation vs Earnings: Sanjeev's compensation has been consistent with company performance over the past year.

CEO

Sanjeev Luther (64 yo)

2.5yrs
Tenure
US$888,813
Compensation

Mr. Sanjeev Luther serves as President, Chief Executive Officer and as a Director at Ernexa Therapeutics Inc. (formerly known as Eterna Therapeutics Inc.) since January 01, 2024. He served as the Chief Exe...

Leadership Team

NamePositionTenureCompensationOwnership
Sanjeev Luther
CEO, President & Director2.5yrsUS$888.81kno data
Robert Pierce
Chief Scientific Officer1.9yrsno datano data
Dorothy Clarke
General Counsel2.5yrsUS$120.78kno data
Kanika Chawla
Senior Vice President of Technical Operations (Consultant)1.5yrsno datano data
2.2yrs
Average Tenure
62yo
Average Age

Experienced Management: ERNA's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sanjeev Luther
CEO, President & Director2.5yrsUS$888.81kno data
Sol Barer
Advisor to the Boardno datano datano data
Jerome Zeldis
Member of Scientific Advisory Board1.6yrsno datano data
William Wexler
Independent Director4.1yrsUS$36.01k0%
$ 0
Michael Andreeff
Member of Scientific Advisory Board5.2yrsno datano data
James Bristol
Independent Chairman of the Board2.8yrsUS$20.84k0%
$ 0
Christopher Rohde
Member of Scientific Advisory Board5.2yrsno datano data
Elena Ratner
Independent Director1.5yrsUS$37.20k0.012%
$ 800.2
Blythe Sather
Member of Scientific Advisory Board1.6yrsno datano data
Amir Jazaeri
Member of Medical Advisory Board1.1yrsno datano data
Peter Cicala
Independent Director2.4yrsUS$14.89k0%
$ 0
Anna Jonsson
Member of Medical Advisory Board1.1yrsno datano data
2.4yrs
Average Tenure
66yo
Average Age

Experienced Board: ERNA's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 11:28
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ernexa Therapeutics Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Jason McCarthyMaxim Group